MOSCOW, March 10. /TASS/. Employees of the US pharmaceutical corporation Pfizer admit the fact of conducting ‘directional evolution’ research for gaining competitive advantages and boosting profits, Chief of Russia’s Radiation, Chemical and Biological Protection Force Igor Kirillov told a briefing devoted to Washington’s military-biological activities on Friday.

He noted the US Senate’s request to the Department of Health on ‘directional evolution’ research conducted by Pfizer. It attempted to estimate the credibility of information received by the American non-profit organization Project Veritas from Pfizer Director of Research and Planning Jordan Walker. Among other things, he said that the company used the possibility of conducting ‘directional evolution’ research for improving the efficiency of its vaccines. Commenting on approaches to the creation of new vaccines, Walker said: <…> why don’t we change the virus ourselves so that we could pre-emptively develop new vaccines.

"Consequently, Pfizer’s employee admits the fact of conducting ‘directional evolution’ research aimed at gaining competitive advantages and boosting profits," Kirillov concluded.

He also drew attention to the remarks by Pfizer’s former employee Karen Kingston, who said that the products of the US pharmaceutical company "by definition, are biological weapons." Kingston cited US legislation that defines biological weapons as any biological agent, toxin or delivery vehicle, including vaccines with mRNA technology (messenger ribonucleic acid - TASS).

Kirillov said that according to information at hand, the development of vaccines of this type had been bankrolled by the US budget since 2017 and by the time commercially available drugs appeared, it had been clear that they could cause the development of secondary diseases and serious complications such as meningitis, anaphylactic shock, acute myocardial infarction and stroke.

According to Kirillov, the side effects after the vaccination were supposed to be treated with medicines manufactured by Pfizer and Moderna, which have already received billions-worth government contacts. "Such an approach makes it possible for American pharmaceutical companies to fully use new pathogens in their interests and receive huge profits," he stressed.